Identifying risk factors for second lung cancers in survivors of lung cancer

Evaluation of genetic, clinical and environmental risk factors to establish effective screening strategies for second primary lung cancer

NIH-funded research Stanford University · NIH-10829797

This study is looking at how genes, health history, and lifestyle can affect the chances of lung cancer survivors getting a second lung cancer, and it aims to improve early detection through a special screening tool and an app that helps predict individual risk based on personal factors.

Quick facts

Grant typeR37 grant
Study typeNIH-funded research
Funding institutionStanford University NIH-funded
Lab location1 site (Stanford, United States)
Project IDNIH-10829797 on NIH RePORTER

What this research studies

This research investigates the genetic, clinical, and environmental factors that contribute to the risk of developing second primary lung cancer (SPLC) in survivors of lung cancer. By utilizing low dose computed tomography (LDCT) screening, the study aims to enhance early detection and establish effective screening strategies tailored for lung cancer survivors. The research includes the development of a risk prediction model that assesses individual risk based on smoking history, tumor characteristics, and medical history, which is accessible through an application called SPLC-RAT. The study also addresses challenges such as validating the risk model across diverse patient populations and incorporating changes in smoking behavior after initial lung cancer diagnosis.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals who have previously been diagnosed with lung cancer and are at risk for developing second primary lung cancer.

Not a fit: Patients who have never been diagnosed with lung cancer or those with other unrelated health conditions may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved screening strategies that significantly reduce the risk of second primary lung cancers in lung cancer survivors.

How similar studies have performed: Previous research has shown promise in developing risk assessment tools for cancer survivors, indicating that this approach has potential for success.

Where this research is happening

Stanford, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.